Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.

The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in combination with anti-PD1 in patients with solid tumors.
Solid Tumor
BIOLOGICAL: Neo-T|COMBINATION_PRODUCT: Toripalimab|COMBINATION_PRODUCT: Tislelizumab
Number of participants with adverse events as assessed by CTCAE v5.0., Keep records the adverse events experienced by subjects in 28 days after the first infusion., one month
Objective Response Rate(ORR), ORR is defined as the proportion of participants with tumor size reduction(CR,PR) assessed by RECIST 1.1 and iRECIST., one year|Disease Control Rate(DCR), DCR is defined as the proportion of participants with tumor size reduction(CR,PR) and stable disease(SD) assessed by RECIST 1.1 and iRECIST., one year|Overall survival(OS), The time from the first infusion of Investigational Product until death., one year|Progression-free survival(PFS), PFS is defined as the time from the first infusion of Investigational Product until objective tumor progression, as assessed by RECIST 1.1 and iRECIST, or death, whichever occurs first., one year|Duration of Response(DOR), DOR refers to the period from the first evaluation of tumor as CR or PR to the first evaluation as PD(Progressive Disease) per RECIST1.1 and iRECIST., one year
This is a single arm, open label and non-randomized clinical study.

6 to12 patients will be enrolled to assess the safety and explore recommended dose of Neo-T combined with anti-PD1.